Brief: Actuate Therapeutics Announces Positive Patient Outcomes From Phase 1 Trial
06/01/2026 14:24
Jan 6 (Reuters) - Actuate Therapeutics Inc ACTU.O: ACTUATE THERAPEUTICS ANNOUNCES POSITIVE PATIENT OUTCOMES FROM PHASE 1 TRIAL IN DIFFICULT-TO-TREAT REFRACTORY PEDIATRIC CANCERS Source text: ID:nGNXb7z4Nf Further company coverage: ACTU.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Actuate Therapeutics
See all newsActuate Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Actuate Therapeutics Inc expected to post a loss of 19 cents a share - Earnings Preview
Health Rounds: Actuate Therapeutics drug improves survival odds in pancreatic cancer trial
Brief: Actuate Therapeutics Announces Plans To Expand Clinical Pipeline, Advancing Elraglusib Tablet Into A Phase 1/2 Clinical Program In Refractory Cancers
Brief: Actuate Therapeutics Inc - Reports Positive Phase 2 Trial Data For Elraglusib - SEC Filing